Menu Close

Jeppson Wealth Management LLC Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

view original post

Jeppson Wealth Management LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 3.3% during the first quarter, Holdings Channel.com reports. The firm owned 3,352 shares of the company’s stock after buying an additional 106 shares during the quarter. Jeppson Wealth Management LLC’s holdings in Johnson & Johnson were worth $594,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Greenleaf Trust raised its stake in shares of Johnson & Johnson by 5.1% in the 1st quarter. Greenleaf Trust now owns 65,666 shares of the company’s stock valued at $11,638,000 after acquiring an additional 3,166 shares during the period. Moody Lynn & Lieberson LLC raised its stake in shares of Johnson & Johnson by 23.8% in the 1st quarter. Moody Lynn & Lieberson LLC now owns 120,656 shares of the company’s stock valued at $21,384,000 after acquiring an additional 23,224 shares during the period. Eads & Heald Wealth Management raised its stake in shares of Johnson & Johnson by 1.2% in the 1st quarter. Eads & Heald Wealth Management now owns 12,705 shares of the company’s stock valued at $2,252,000 after acquiring an additional 150 shares during the period. ARGI Investment Services LLC raised its stake in shares of Johnson & Johnson by 6.6% in the 1st quarter. ARGI Investment Services LLC now owns 88,312 shares of the company’s stock valued at $15,651,000 after acquiring an additional 5,469 shares during the period. Finally, Greatmark Investment Partners Inc. raised its stake in shares of Johnson & Johnson by 3.1% in the 1st quarter. Greatmark Investment Partners Inc. now owns 89,405 shares of the company’s stock valued at $15,845,000 after acquiring an additional 2,690 shares during the period. 68.78% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In other news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider William Hait sold 29,699 shares of the company’s stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total value of $5,452,142.42. Following the completion of the sale, the insider now owns 80,236 shares in the company, valued at approximately $14,729,724.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The disclosure for this sale can be found here. In the last quarter, insiders sold 78,161 shares of company stock worth $13,895,302. 0.35% of the stock is currently owned by insiders.

Analysts Set New Price Targets

JNJ has been the topic of a number of research analyst reports. Raymond James boosted their price target on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Credit Suisse Group lifted their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Citigroup dropped their price objective on shares of Johnson & Johnson from $210.00 to $205.00 in a report on Tuesday, May 17th. Finally, Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a report on Friday, July 8th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $191.29.

Johnson & Johnson Trading Down 2.2 %

NYSE JNJ opened at $174.23 on Tuesday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The stock has a market capitalization of $458.47 billion, a PE ratio of 23.48, a price-to-earnings-growth ratio of 3.54 and a beta of 0.63. The firm has a 50 day moving average of $176.69 and a two-hundred day moving average of $174.39.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share for the quarter, topping the consensus estimate of $2.60 by $0.07. The business had revenue of $23.43 billion during the quarter, compared to the consensus estimate of $23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The company’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.59 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.19 EPS for the current fiscal year.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.